• Wiley Online Library will be disrupted on 18 May from 10:00-12:00 BST (05:00-07:00 EDT) for essential maintenance
You have free access to this content

Evaluating joint effects of induction–salvage treatment regimes on overall survival in acute leukaemia

  1. Abdus S. Wahed1,
  2. Peter F. Thall2

Article first published online: 27 JUL 2012

DOI: 10.1111/j.1467-9876.2012.01048.x

Issue

Journal of the Royal Statistical Society: Series C (Applied Statistics)

Journal of the Royal Statistical Society: Series C (Applied Statistics)

Volume 62, Issue 1, pages 67–83, January 2013

Additional Information

How to Cite

Wahed, A. S. and Thall, P. F. (2013), Evaluating joint effects of induction–salvage treatment regimes on overall survival in acute leukaemia. Journal of the Royal Statistical Society: Series C (Applied Statistics), 62: 67–83. doi: 10.1111/j.1467-9876.2012.01048.x

Author Information

  1. 1

    University of Pittsburgh, USA

  2. 2

    University of Texas M. D. Anderson Cancer Center, Houston, USA

* Address for correspondence: Abdus S. Wahed, Department of Biostatistics, University of Pittsburgh, 318C, 130 DeSoto Street, Pittsburgh, PA 15261, USA. Email: wahed@pitt.edu

Publication History

  1. Issue published online: 18 DEC 2012
  2. Article first published online: 27 JUL 2012
  3. [Received February 2011. Final revision February 2012]

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (699K)

References

  • Estey, E. H., Shen, Y. and Thall, P. F. (2000) Effect of time to complete remission on subsequent survival and disease-free survival in AML, RAEB-t, and RAEB. Blood, 95, 72–77.
  • Estey, E. H., Thall, P. F., Pierce, S., Cortes, J., Beran, M., Kantarjian, H., Keating, M. J., Andreeff, M. and Freireich, E. (1999) Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood, 93, 2478–2484.
  • Estey, E. H., Thall, P. F., Pierce, S., Kantarjian, H. and Keating, M. (1997) T treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J. Clin. Oncol., 15, 483–490.
  • Holland, P. (1986) Statistics and causal inference. J. Am. Statist. Ass., 81, 945–960.
  • Lavori, P. W. and Dawson, R. (2000) A design for testing clinical strategies: biased adaptive within-subject randomization. J. R. Statist. Soc. A, 163, 29–38.
    Direct Link:
  • Lavori, P. and Dawson, R. (2004) Dynamic treatment regimes: practical design considerations. Clin. Trials, 1, 9–20.
  • Lunceford, J., Davidian, M. and Tsiatis, A. A. (2002) Estimation of the survival distribution of treatment policies in two-stage randomization designs in clinical trials. Biometrics, 58, 48–57.
    Direct Link:
  • Murphy, S. A. (2003) Optimal dynamic treatment regimes (with discussion). J. R. Statist. Soc. B, 65, 331–366.
    Direct Link:
  • Murphy, S. A. (2005) An experimental design for the development of adaptive treatment strategies. Statist. Med., 24, 1455–1481.
    Direct Link:
  • Murphy, S. A., van der Laan, M., Robins, J. M. and CPPRG (2001) Marginal mean models for dynamic treatment regimes. J. Am. Statist. Ass., 96, 1410–1424.
  • Robins, J. M. (1986) A new approach to causal inference in mortality studies with sustained exposure periods—application to control of the healthy survivor effect. Math. Modlng, 7, 1393–1512.
  • Robins, J. M. (1997) Causal inference from complex longitudinal data latent variable modeling and applications to causality. Lect. Notes Statist., 120, 69–117.
  • Robins, J. M. (2004) Optimal structural nested models for optimal sequential decisions. In Proc. 2nd Seattle Symp. Biostatistics (eds D. Y. Lin and P. Heagerty). New York: Springer
  • Robins, J. M., Hernan, M. A. and Brumback, B. (2000) Marginal structural models and causal inference in epidemiology. Epidemiology, 11, 550–560.
  • Robins, J. M., Orellana, L., Hernan, M. and Rotnitzky, A. (2008) Estimation and extrapolation of optimal treatment and testing strategies. Statist. Med., to be published.
    Direct Link:
  • Robins, J. M. and Rotnitzky, A. (1992) Recovery of information and adjustment for dependent censoring using surrogate markers. In AIDS Epidemiology, Methodological Issues (eds N. Jewell, K. Dietz and V. Farewellpp. 297–331. Boston: Birkhäuser.
  • Schwarz, G. (1978) Estimating the dimension of a model. Ann. Statist., 6, 461–464.
  • Shen, Y. and Thall, P. F. (1998) Parametric likelihoods for multiple non-fatal competing risks and death. Statist. Med., 17, 999–1016.
    Direct Link:
  • Thall, P. F., Logothetis, C., Pagliaro, L., Wen, S., Brown, M. A., Williams, D. and Millikan, R. (2007) Adaptive therapy for androgen independent prostate cancer: a randomized selection trial including four regimens. J. Natn. Cancer Inst., 99, 1613–1622.
  • Thall, P. F., Millikan, R. and Sung, H. G. (2000) Evaluating multiple treatment courses in clinical trials. Statist. Med., 19, 1011–1028.
    Direct Link:
  • Thall, P. F., Sung, H.-G. and Estey, E. H. (2002) Selecting therapeutic strategies based on efficacy and death in multi-course clinical trials. J. Am. Statist. Ass., 97, 29–39.
  • Wahed, A. S. and Tsiatis, A. A. (2004) Optimal estimator for the survival distribution and related quantities for treatment policies in two-stage randomization designs in clinical trials. Biometrics, 60, 124–133.
    Direct Link:
  • Wahed, A. S. and Tsiatis, A. A. (2006) Semiparametric efficient estimation of survival distribution for treatment policies in two-stage randomization designs in clinical trials with censored data. Biometrika, 93, 163–177.
  • Zhao, Y., Kosorok, M. R. and Zeng, D. (2009) Reinforcement learning design for cancer clinical trials. Statist. Med., 28, 3294–3315.
    Direct Link:
View Full Article (HTML) Get PDF (699K)